The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceAidan Toner, Sharon A. Glynn|British Journal of Cancer|2013Cited by 12
Preclinical assessment of the novel compound EL102 in prostate cancerAidan Toner|ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway)|2015Cited by 0